AxoGen's stock surged 14.24% in pre-market trading on Tuesday, following the release of its first-quarter 2026 financial results that exceeded analyst expectations.

The medical technology company reported quarterly revenue of $61.5 million, surpassing the IBES estimate of $57.7 million. The company also posted an adjusted EBITDA of $5.7 million and an adjusted net income of $4.1 million for the quarter, alongside a robust gross margin of 75.2%.

Investor sentiment was further bolstered by the company's forward-looking statements, which included a full-year revenue outlook of $270 million and an expected gross margin between 74% and 76% for 2026.